At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
Blood eosinophil count is becoming increasingly recognized by the respiratory specialist community as a clinically relevant biomarker to help estimate affective management strategies, but the use is still...
Lead author Per Ljungman, MD, answers our questions about the recently published guidelines on managing cytomegalovirus infection in patients with hematological malignancies.
Newly published research indicates that red blood cell transfusions may be tied to the risk for venous thromboembolism. Recently, Consultant360 spoke with lead study author Ruchika Goel, MD, MPH, about the...
